دواعي استعمال تيبازولاكس اس ار 0.5مجم 50 اقراص

Tibazolax SR alprazolam 0.5 mg sustained-release tablets, pack of 50 (Hochster / Sigma, Egypt); benzodiazepine anxiolytic.

• Panic disorder with or without agoraphobiaالفئة: AdultsDailyMed (US National Library of Medicine)

• Most common (>=5% and twice placebo): somnolence, memory impairment, dysarthria, abnormal coordination, ataxia, decreased libido, constipation, nausea.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• Hypersensitivity to alprazolam or other benzodiazepines; concomitant strong CYP3A inhibitors (e.g. ketoconazole, itraconazole) except ritonavir.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• Boxed warning: concomitant opioids may cause profound sedation, respiratory depression, coma and death; risk of abuse, misuse and addiction; physical dependence with potentially life-threatening withdrawal on abrupt discontinuation.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• Avoid driving, machinery and alcohol/CNS depressants; caution in depression; neonatal sedation and withdrawal after use in pregnancy.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• OpioidsProfound sedation, respiratory depression, coma and death.DailyMed (US National Library of Medicine)
• Strong CYP3A inhibitors (ketoconazole, itraconazole)Contraindicated.DailyMed (US National Library of Medicine)
• RitonavirReduce alprazolam dose by half when starting together; restore after 10-14 days.DailyMed (US National Library of Medicine)

• Late-pregnancy use may cause neonatal sedation and withdrawal; observational data do not show a clear association with major birth defects. Monitor exposed neonates.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• Breastfeeding is not recommended during treatment (infant sedation, poor feeding and withdrawal reported).نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• ألبرازولام: Binds the benzodiazepine site of GABA-A receptors, enhancing GABA-mediated inhibition.